UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 16, 2006



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)




           Delaware                       0-16375               94-3018487
          ---------                       --------               ----------
(State or other jurisdiction of    (Commission File Number)   (I.R.S. Employer
incorporation or organization)                               Identification No.)


                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
              (Address and telephone number of principal executive
                               offices) (Zip Code)


                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)
[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)
[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))



<PAGE>


Section 8 - Other Events
------------------------

Item 8.01 Other Events.

     On January 3, 2006,  ThermoGenesis Corp. (the "Company") announced that the
Center for Biologics  Evaluation and Research ("CBER") notified the Company that
it was reviewing the Company's  pre-market  application ("PMA") for its CryoSeal
FS System ("CryoSeal").  The PMA submission was based on clinical results from a
Phase III trial  evaluating the safety and efficacy of CryoSeal as an adjunct to
hemostasis in liver resection surgery against the control, INSTAT(R), a collagen
absorbable hemostat.  If approved,  CryoSeal would be the only fibrin sealant on
the market that is produced from the patient's own blood,  and an alternative to
conventional fibrin sealants that are derived from bovine tissue or pooled human
blood.

     Although  CBER  acknowledged  that it was  reviewing  the Company's PMA for
CryoSeal,  no assurance can be given that CBER will not require  further testing
and clinical data, or that CryoSeal will ultimately be approved by the FDA to be
marketed  in the United  States.  If further  testing and  clinical  studies are
required,   there  can  be  no  assurance  that  the  clinical  studies  can  be
successfully  completed within the Company's  expected time frame and budget, or
that such studies will provide required findings for approval. If the Company is
unable to receive FDA approval for CryoSeal,  the Company's business,  financial
condition and results of operations could be adversely affected.

     Additional  information  can be  found on the  press  release  attached  as
Exhibit 99.


Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

   Exhibit No.      Exhibit Description
   -----------      -------------------

      99            Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"



<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                        THERMOGENESIS CORP.,
                                        a Delaware Corporation


Dated:  January 16, 2006                /s/ Matthew Plavan
                                        ------------------------------------
                                        Matthew Plavan,
                                        Chief Financial Officer


<PAGE>


                                  EXHIBIT INDEX


      Exhibit No.                       Description
      -----------                       -----------

          99        Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"
[{"type": "8-K", "sequence": "1", "filename": "for011706.txt", "secsgml_size_bytes": 4986}]
{"company-data": {"conformed-name": "THERMOGENESIS CORP", "cik": "0000811212", "assigned-sic": "3821", "irs-number": "943018487", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-82900", "film-number": "06533745"}, "business-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742", "phone": "9168585100"}, "mail-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742"}, "former-company": {"former-conformed-name": "INSTA COOL INC OF NORTH AMERICA", "date-changed": "19920703"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 16, 2006

                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)

           Delaware                       0-16375               94-3018487
          ---------                       --------               ----------
(State or other jurisdiction of    (Commission File Number)   (I.R.S. Employer
incorporation or organization)                               Identification No.)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
              (Address and telephone number of principal executive
                               offices) (Zip Code)

                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)
[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)
[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 8 - Other Events
------------------------

Item 8.01 Other Events.

     On January 3, 2006,  ThermoGenesis Corp. (the "Company") announced that the
Center for Biologics  Evaluation and Research ("CBER") notified the Company that
it was reviewing the Company's  pre-market  application ("PMA") for its CryoSeal
FS System ("CryoSeal").  The PMA submission was based on clinical results from a
Phase III trial  evaluating the safety and efficacy of CryoSeal as an adjunct to
hemostasis in liver resection surgery against the control, INSTAT(R), a collagen
absorbable hemostat.  If approved,  CryoSeal would be the only fibrin sealant on
the market that is produced from the patient's own blood,  and an alternative to
conventional fibrin sealants that are derived from bovine tissue or pooled human
blood.

     Although  CBER  acknowledged  that it was  reviewing  the Company's PMA for
CryoSeal,  no assurance can be given that CBER will not require  further testing
and clinical data, or that CryoSeal will ultimately be approved by the FDA to be
marketed  in the United  States.  If further  testing and  clinical  studies are
required,   there  can  be  no  assurance  that  the  clinical  studies  can  be
successfully  completed within the Company's  expected time frame and budget, or
that such studies will provide required findings for approval. If the Company is
unable to receive FDA approval for CryoSeal,  the Company's business,  financial
condition and results of operations could be adversely affected.

     Additional  information  can be  found on the  press  release  attached  as
Exhibit 99.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

   Exhibit No.      Exhibit Description
   -----------      -------------------

      99            Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        THERMOGENESIS CORP.,
                                        a Delaware Corporation

Dated:  January 16, 2006                /s/ Matthew Plavan
                                        ------------------------------------
                                        Matthew Plavan,
                                        Chief Financial Officer
EXHIBIT INDEX

      Exhibit No.                       Description
      -----------                       -----------

          99        Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"